Jefferies Initiates Coverage on $LEU with Hold Rating, PT $169 Analyst comments: "LEU offers long-dated optionality on the U.S. nuclear fuel supply rebuild without taking reactor construction risk. Its U.S.-origin centrifuge platform, NRC-licensed HALEU capability, DOE support, and $3.9bn backlog position it for domestic LEU/HALEU growth. The shares appear to discount a successful ramp by 2030; upside hinges, in our view, on capturing upside if the LEU/HALEU market is tighter in the 2030s. Centrus is transitioning from a nuclear fuel supplier and technical-services provider into a strategic U.S. enrichment platform. The core long-term thesis is not near-term earnings, which remain lumpy, but whether LEU can convert its unique sole-source U.S.-origin technology, NRC-licensed HALEU position, DOE-backed deployment work, and contingent commercial backlog into scaled domestic LEU/HALEU capacity. Gas centrifuge enrichment is structurally more energy efficient than legacy gaseous diffusion, supporting both cost and sustainability advantages." Analyst: Laurence Alexander